TrialJournal of autoimmunity2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Michelle Rosenzwajg et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
151 papers cite itlatest 60 shown
this papertrialcites it